litlas
Log inCreate account

Volker Heinemann

Active 1988–2025

200
Papers
34,231
Citations
90
h-index
189
i10-index

Citations

Citations per year for Volker Heinemann1990: 3 citations1991: 7 citations1992: 8 citations1993: 10 citations1994: 10 citations1995: 4 citations1996: 22 citations1997: 21 citations1998: 21 citations1999: 27 citations2000: 28 citations2001: 21 citations2002: 25 citations2003: 32 citations2004: 28 citations2005: 25 citations2006: 27 citations2007: 48 citations2008: 70 citations2009: 70 citations2010: 83 citations2011: 84 citations2012: 113 citations2013: 133 citations2014: 140 citations2015: 194 citations2016: 184 citations2017: 341 citations2018: 290 citations2019: 1,160 citations2020: 1,314 citations2021: 1,374 citations2022: 1,023 citations2023: 803 citations2024: 1,404 citations2025: 680 citations2026: 23 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,443 citing papers, 18.9% of this breakdownChina: 1,536 citing papers, 11.9% of this breakdownGermany: 1,035 citing papers, 8% of this breakdownItaly: 965 citing papers, 7.5% of this breakdownUnited Kingdom: 725 citing papers, 5.6% of this breakdownFrance: 617 citing papers, 4.8% of this breakdownJapan: 545 citing papers, 4.2% of this breakdownSpain: 467 citing papers, 3.6% of this breakdownNetherlands: 451 citing papers, 3.5% of this breakdownCanada: 295 citing papers, 2.3% of this breakdownSouth Korea: 280 citing papers, 2.2% of this breakdownBelgium: 277 citing papers, 2.1% of this breakdown
0%18.9%Other 25.4%

Institutions

Fields

  • Medicine74.7%
  • Biochemistry, Genetics and Molecular Biology16.8%
  • Immunology and Microbiology2.3%
  • Computer Science1.6%
  • Engineering1.4%
  • Materials Science1%
  • Other2.2%

Topics

  • Colorectal Cancer Treatments and Studies6.9%
  • Pancreatic and Hepatic Oncology Research6.7%
  • Cancer Genomics and Diagnostics4%
  • Gastric Cancer Management and Outcomes3.7%
  • Cancer Immunotherapy and Biomarkers3.4%
  • Cholangiocarcinoma and Gallbladder Cancer Studies3%
  • Other72.3%

Coauthors

All papers

Open in search
  1. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

    Authors: Salah‐Eddin Al‐Batran, Nils Homann, Claudia Pauligk, Thorsten Oliver Goetze, Johannes Meiler, Stefan Kasper, Hans‐Georg Kopp, Frank Mayer, Georg Martin Haag, Kim Barbara Luley, Udo Lindig, Wolff Schmiegel, Michael Pohl, Jan Stoehlmacher, Gunnar Folprecht, Stephan Probst, Nicole Prasnikar, Wolfgang Fischbach, Rolf Mahlberg, Jörg Trojan, Michael Koenigsmann, Uwe M. Martens, Peter Thuss‐Patience, Matthias Egger, Andreas Block, Volker Heinemann, Gerald Illerhaus, Markus Moehler, Michael Schenk, Frank Kullmann, Dirk Behringer, Michael Heike, Daniel Pink, Christian Teschendorf, Carmen Löhr, Helga Bernhard, Gunter Schuch, Volker Rethwisch, Ludwig Fischer von Weikersthal, Jörg T. Hartmann, Michael Kneba, S Daum, Karsten Schulmann, J. Weniger, Sebastian Belle, Timo Gaiser, Fuat Oduncu, Martina Güntner, Wael Hozaeel, Alexander Reichart, Elke Jäger, Thomas Kraus, Stefan Mönig, Wolf O. Bechstein, Martin Schüler, Harald Schmalenberg, Ralf‐Dieter Hofheinz - The Lancet 2019 cited by 2,583

  2. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, Richard S. Finn, Junji Furuse, Zhenggang Ren, Thomas Yau, Heinz‐Josef Klümpen, Stephen L. Chan, Masato Ozaka, Chris Verslype, Mohamed Bouattour, Joon Oh Park, Olga Barajas, Uwe Pelzer, Juan W. Valle, Li Yu, Usha Malhotra, Abby B. Siegel, Julien Edeline, Arndt Vogel, Mehmet Akce, Inmaculada Alés Díaz, Gustavo R. Alves, Sumitra Anand, Çağatay Arslan, Jamil Asselah, Eric Assénat, Eric Assenat, Li‐Yuan Bai, Yuxian Bai, Olga Barajas, Susan E. Bates, Stephen Begbie, Irit Ben‐Aharon, Nina Beri, Marie‐Luise Berres, Jean‐Frédéric Blanc, Ivan Borbath, Robert Bordonaro, Mohamed Bouattour, Giovanni Brandi, Adam M. Burgoyne, Kritiya Butthongkomvong, Marcos Pedro Guedes Camandaroba, Ke Cao, Marcela Carballido, Marcela Carballido, Jen‐Shi Chen, Ming‐Huang Chen, Ming-Huang Chen, Ashley Cheng, Tai‐Jan Chiu, Hye Jin Choi, Hong Jae Chon, Joëlle Collignon, Antonio Cubillo Gracián, S. Lindsey Davis, Ricardo Saraiva de Carvalho, D.J.A. de Groot, Anne Demols, Judith de Vos, Maria Diab, Jacob C. Easaw, Martin Eatock, Julien Edeline, Rawad Elias, Fredericus Eskens, Alfredo Falcone, Plinio Fernández, Richard S. Finn, Fábio Franke, Masayuki Furukawa, Junji Furuse, Olumide B. Gbolahan, Karen Geboes, Keri-Lee Geneser, Zhimin Geng, Ravit Geva, Roopinder Gillmore, Thorsten Oliver Goetze, Hongfeng Gou, Julieta Grasselli, Shanzhi Gu, Mahmut Gümüş, Nadia Haj Mohammad, Chunyi Hao, Hakan Harputluoğlu, Hassan Hatoum, Volker Heinemann, Wang Kwong Ho, Chiun Hsu, Ayala Hubert, Jun‐Eul Hwang, Mevlüde İnanç, Soledad Iseas, Vaishnavi Jeyasingam, Paula Jiménez Fonseca, Warren Joubert, Jitlada Juengsamarn and 116 more - The Lancet 2023 cited by 1,025

  3. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

    Authors: Eric Van Cutsem, Andrés Cervantes, René Adam, Alberto Sobrero, J. Han van Krieken, Dan Aderka, E. Aranda Aguilar, Alberto Bardelli, Al B. Benson, G. Bodoky, Fortunato Ciardiello, André D’Hoore, Eduardo Díaz‐Rubio, Jean‐Yves Douillard, Michel Ducreux, Alfredo Falcone, Axel Grothey, Thomas Gruenberger, Karin Haustermans, Volker Heinemann, Paulo M. Hoff, C.-H. Köhne, Roberto Labianca, Pierre Laurent‐Puig, Brigette Ma, Tim Maughan, Kei Muro, Nicola Normanno, Pia Österlund, Wim J.G. Oyen, Demetris Papamichael, George Pentheroudakis, Per Pfeiffer, Timothy Price, Cornelis J.A. Punt, Jens Ricke, A. Roth, Ramón Salazar, Werner Scheithauer, Hans‐Joachim Schmoll, Josep Tabernero, Julien Taı̈eb, Sabine Tejpar, Harpreet Wasan, Takayuki Yoshino, Aziz Zaanan, Dirk Arnold - Annals of Oncology 2016 cited by 3,449

  4. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma

    Authors: Eric Van Cutsem, Margaret A. Tempero, Darren Sigal, Do‐Youn Oh, Nicola Fazio, Teresa Macarulla, Erika Hitre, Pascal Hammel, Andrew Hendifar, Susan E. Bates, Chung‐Pin Li, Sunil R. Hingorani, Christelle de la Fouchardière, Anup Kasi, Volker Heinemann, Anthony Maraveyas, Nathan Bahary, Laura Layos, Vaibhav Sahai, Lei Zheng, Jill Lacy, Joon Oh Park, Fabienne Portales, Paul E. Oberstein, Wilson Wu, Dimitrios Chondros, Andrea J. Bullock, on behalf of the HALO 109-301 Investigators - Journal of Clinical Oncology 2020 cited by 446

  5. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial

    Authors: Marwan G Fakih, Scott Kopetz, Yasutoshi Kuboki, Tae Won Kim, Pamela N Munster, John C Krauss, Gerald S Falchook, Sae-Won Han, Volker Heinemann, Kei Muro, John H Strickler, David S Hong, Crystal S Denlinger, Gustavo Girotto, Myung-Ah Lee, Haby Henary, Qui Tran, Joseph K Park, Gataree Ngarmchamnanrith, Hans Prenen, Timothy J Price - The Lancet Oncology 2021 cited by 288

  6. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

    Authors: Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling‐Kaiser, Salah‐Eddin Al‐Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, G. Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Jörg Hielscher, Michael Scholz, Sebastian Müller, Hartmut Link, N. Niederle, A. Rost, Heinz‐Gert Höffkes, Markus Moehler, Reinhard Udo Lindig, Dominik Paul Modest, Lisa Rossius, Thomas Kirchner, Andreas Jung, Sebastian Stintzing - The Lancet Oncology 2014 cited by 1,741

  7. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database

    Authors: Jan Franko, Qian Shi, Jeffrey P. Meyers, Tim Maughan, Richard Adams, Michel Seymour, Leonard B. Saltz, Cornelis J.A. Punt, Miriam Koopman, Christophe Tournigand, Niall C. Tebbutt, Eduardo Díaz‐Rubio, John Souglakos, Alfredo Falcone, Benoist Chibaudel, Volker Heinemann, Joseph Moen, Aimery de Gramont, Daniel J. Sargent, Axel Grothey - The Lancet Oncology 2016 cited by 660

  8. Advances in cancer immunotherapy 2019 – latest trends

    Authors: Stephan Krüger, Matthias Ilmer, Sebastian Kobold, Bruno L. Cadilha, Stefan Endres, Steffen Ormanns, Gesa Schuebbe, Bernhard W. Renz, Jan DʼHaese, Hans Anton Schloesser, Volker Heinemann, Marion Subklewe, Stefan Boeck, Jens Werner, Michael von Bergwelt‐Baildon - Journal of Experimental & Clinical Cancer Research 2019 cited by 588

  9. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

    Authors: Dominik Paul Modest, Ingrid Ricard, Volker Heinemann, S. Hegewisch-Becker, Wolff Schmiegel, Rainer Porschen, Sebastian Stintzing, Ullrich Graeven, Dirk Arnold, Ludwig Fischer von Weikersthal, Clemens Gießen-Jung, Arndt Stahler, Hans‐Joachim Schmoll, Andreas Jung, Thomas Kirchner, Andrea Tannapfel, Anke Reinacher‐Schick - Annals of Oncology 2016 cited by 344

  10. Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

    Authors: Margaret A. Tempero, Uwe Pelzer, Eileen M. O’Reilly, Jordan M. Winter, Do‐Youn Oh, Chung‐Pin Li, Giampaolo Tortora, Heung-Moon Chang, Charles D. Lopez, Tanios Bekaii‐Saab, Andrew H. Ko, Armando Santoro, Joon Oh Park, Marcus Smith Noel, Giovanni Luca Frassineti, Yan‐Shen Shan, Andrew Dean, Hanno Riess, Eric Van Cutsem, Jordan Berlin, Philip Philip, Malcolm J. Moore, David Goldstein, Josep Tabernero, Mingyu Li, Stefano Ferrara, Yvan Le Bruchec, George Zhang, Brian Lu, Andrew V. Biankin, Michele Reni, Richard A. Epstein, Paul L. Vasey, Jeremy Shapiro, Matthew Burge, Yu Jo Chua, Marion Harris, Nick Pavlakis, Niall C. Tebbutt, Gerald W. Prager, Christian Dittrich, Friedrich Längle, Kathrin Philipp‐Abbrederis, Richard Greil, Herbert Stöger, Michael Girschikofsky, Thomas Kuehr, Jean–Luc Van Laethem, Stéphanie Laurent, Neesha C. Dhani, Yoo Joung Ko, Scot Dowden, Petr Kavan, Mustapha Édouard Tehfe, Eugen Kubala, Milan Kohoutek, Per Pfeiffer, Mette Yilmaz, Vibeke K. Parner, Tapio Salminen, Leena‐Maija Soveri, Eija Korkeila, Pia Österlund, Julien Taı̈eb, David Tougeron, Pascal Artru, François‐Xavier Caroli‐Bosc, Rosine Guimbaud, Antony Turpin, Thomas Walter, Jean‐Baptiste Bachet, Volker Kunzmann, Florian Kreth, Andreas De Block, Marino Venerito, Helmut Oettle, Meinolf Karthaus, Jörg Trojan, Gunnar Folprecht, Markus M. Lerch, Frank Kullmann, Marcel Reiser, Volker Heinemann, Marcus‐Alexander Wörns, H. Schulz, Benjamin Garlipp, Thomas Yau, Lam Stephen Chan, Balázs Juhász, László Landherr, Tamás Pintér, G. Bodoky, Zsuzsanna Kahán, Raymond McDermott, Derek G. Power, Luca Gianni, Salvatore Siena, Michèle Milella, Alfredo Falcone, Rossana Berardi and 87 more - Journal of Clinical Oncology 2022 cited by 132

  11. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials

    Authors: Dirk Arnold, B. Lueza, Jean-Yves Douillard, Marc Peeters, Heinz‐Josef Lenz, Alan P. Venook, Volker Heinemann, Eric Van Cutsem, Jean‐Pierre Pignon, Josep Tabernero, Andrés Cervantes, Fortunato Ciardiello - Annals of Oncology 2017 cited by 836

  12. Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer

    Authors: Eric Van Cutsem, Heinz‐Josef Lenz, Claus-Henning Köhne, Volker Heinemann, Sabine Tejpar, I. Melezínek, Frank Beier, Christopher Stroh, Philippe Rougier, J. Han van Krieken, Fortunato Ciardiello - Journal of Clinical Oncology 2015 cited by 800

  13. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials

    Authors: Julian Walter Holch, Ingrid Ricard, Sebastian Stintzing, Dominik Paul Modest, Volker Heinemann - European Journal of Cancer 2016 cited by 533

  14. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial

    Authors: Volker Kunzmann, Jens T. Siveke, Hana Algül, Eray Goekkurt, Gabriele Margareta Siegler, Uwe M. Martens, Dirk Waldschmidt, Uwe Pelzer, Martin Fuchs, Frank Kullmann, Stefan Boeck, Thomas J. Ettrich, Swantje Held, Ralph Keller, Ingo Klein, Christoph‐Thomas Germer, H. J. Stein, Helmut Friess, Marcus Bahra, Ralf Jakobs, Ingo Hartlapp, Volker Heinemann, Elke Hennes, Udo Lindig, Thomas Geer, Michael Ståhl, M. Senkal, Thomas Südhoff, Matthias Egger, Christoph Kahl, Christina Große-Thie, Marcel Reiser, Stefan Mahlmann, Peter Fix, H. Schulz, Georg Maschmeyer, Wolfgang Blau - ˜The œLancet. Gastroenterology & hepatology 2020 cited by 197

  15. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer

    Authors: Sabine Tejpar, Sebastian Stintzing, Fortunato Ciardiello, Josep Tabernero, Eric Van Cutsem, Frank Beier, Regina Esser, Heinz‐Josef Lenz, Volker Heinemann - JAMA Oncology 2016 cited by 722

  16. Addressing the challenges of pancreatic cancer: Future directions for improving outcomes

    Authors: Manuel Hidalgo, Stefano Cascinu, Jörg Kleeff, Roberto Labianca, Matthias Löhr, John P. Neoptolemos, Francisco X. Real, Jean‐Luc Van Laethem, Volker Heinemann - Pancreatology 2014 cited by 507

  17. FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial

    Authors: Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Florian Kaiser, Salah-Edin Al-Batran, Tobias Heintges, Christoph Lerchenmüller, Christoph Kahl, G. Seipelt, Frank Kullmann, Markus Moehler, Werner Scheithauer, Swantje Held, Lisa Miller‐Phillips, Dominik Paul Modest, Andreas Jung, Thomas Kirchner, Sebastian Stintzing - British Journal of Cancer 2020 cited by 188

  18. Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study

    Authors: Akihito Kawazoe, Rui‐Hua Xu, Pilar García‐Alfonso, Maria Passhak, Hao‐Wei Teng, Ardaman Shergill, Mahmut Gümüş, Camilla Qvortrup, Sebastian Stintzing, Kathryn Towns, Tae Won Kim, Kai‐Keen Shiu, Juan Cundom, Sumitra Ananda, A. A. Lebedinets, Rong Fu, Rishi Jain, David E. Adelberg, Volker Heinemann, Takayuki Yoshino, Elena Élez, the LEAP-017 Investigators, Juan Cundom, Ezequiel Slutsky, Julieta Grasselli, Luis Fein, Luciana Bella Quero, Warren Joubert, Peter Gibbs, Timothy Price, Matthew Burge, Sumitra Ananda, Muhammad A. Khattak, Bruce Colwell, Félix Couture, Brandon M. Meyers, Kathryn Towns, Michael B. Sawyer, Lucas Sidéris, Rui‐Hua Xu, Wei Wang, Hongming Pan, Per Pfeiffer, Lars Henrik Jensen, Camilla Qvortrup, Sebastian Stintzing, Dirk Arnold, Sylvie Lorenzen, Stefan Kubicka, Reinhard Depenbusch, Maria Passhak, Ravit Geva, Ayala Hubert, Einat Shacham‐Shmueli, Gleb Kornev, Akihito Kawazoe, Toshiki Masuishi, Atsuo Takashima, Hiroki Hara, Hisato Kawakami, Nozomu Machida, Kentaro Yamazaki, Hisateru Yasui, Akihito Tsuji, Taito Esaki, Kensei Yamaguchi, Tae‐You Kim, Joong Bae Ahn, Myung Ah Lee, Tae Won Kim, Joon Oh Park, Soo Hyun Lee, Р. В. Орлова, V. O. Sarzhevskiy, Marina Sekacheva, S. Tjulandin, Oksana Shirokova, A.I. Iskhakova Iskhakova, A. A. Lebedinets, Paula Jiménez Fonseca, F. Rivera Herrero, Elena Elez Fernandez, Pilar Alfonso, M.J. Gómez Reina, Kun‐Huei Yeh, Hao‐Wei Teng, Tsai Sheng Yang, Hwei‐Ming Wang, Yu‐Min Yeh, Mustafa Özgüroğlu, Mahmut Gumus, Şuayib Yalçın, Bülent Erdoğan, Umut Demırcı, Pınar Gürsoy, Hakan Harputluoğlu, Atakan Demir, Kai‐Keen Shiu, Ewan Brown, Paul J. Ross and 13 more - Journal of Clinical Oncology 2024 cited by 77

  19. nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

    Authors: David Goldstein, Robert H. El-Maraghi, Pascal Hammel, Volker Heinemann, Volker Kunzmann, Javier Sastre, Werner Scheithauer, Salvatore Siena, Josep Tabernero, Luís Teixeira, Giampaolo Tortora, Jean‐Luc Van Laethem, Rosemary Young, Darryl Penenberg, Brian Lu, Alfredo Romano, Daniel D. Von Hoff - JNCI Journal of the National Cancer Institute 2015 cited by 663

  20. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial

    Authors: Sebastian Stintzing, Dominik Paul Modest, Lisa Rossius, Markus M. Lerch, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling‐Kaiser, Salah‐Eddin Al‐Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, G. Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Swantje Held, Clemens Gießen-Jung, Markus Moehler, A. Jagenburg, Thomas Kirchner, Andreas Jung, Volker Heinemann - The Lancet Oncology 2016 cited by 418

  21. Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial

    Authors: Beate Rau, Hauke Lang, Alfred Koenigsrainer, Ines Gockel, Horst-Guenter Rau, Hendrik Seeliger, C. Lerchenmueller, Daniel Reim, Roger Wahba, Martin K. Angele, Steffen Heeg, Tobias Keck, Arved Weimann, Stefan A. Topp, Pompiliu Piso, Andreas Brandl, Silke Schuele, Peter Jo, Johann Pratschke, Sandra Wegel, Alexander Rehders, Nicolas Moosmann, Jochen Gaedcke, Volker Heinemann, Evelyn Trips, Markus Loeffler, Peter M. Schlag, Peter Thuss‐Patience - Journal of Clinical Oncology 2023 cited by 128

  22. FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study

    Authors: Sebastian Stintzing, Kathrin Heinrich, David Tougeron, Dominik Paul Modest, Ingo Schwaner, Jan Eucker, Rudolf Pihusch, Martina Stauch, Florian Kaiser, Christoph Kahl, Meinolf Karthaus, Christian D. Muller, Christof Burkart, Anke Reinacher‐Schick, Stefan Kasper‐Virchow, Ludwig Fischer von Weikersthal, Beate Krammer‐Steiner, Gerald W. Prager, Julien Taı̈eb, Volker Heinemann - Journal of Clinical Oncology 2023 cited by 68

  23. Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

    Authors: Antje Wick, Oliver Bähr, Martin Schüler, Kristoffer Staal Rohrberg, Sant P. Chawla, Filip Jankú, David Schiff, Volker Heinemann, Yoshitaka Narita, Heinz‐Josef Lenz, Masafumi Ikeda, Yuichi Ando, Wolfgang Wick, Joachim P. Steinbach, Michael C. Burger, Katharina J. Wenger, Ulrik Lassen, Kamalesh K. Sankhala, Cristiana Roggia, Isabelle Genvresse, Catya Munhoz, Christine Rentzsch, Susanne Reschke, Simon Langer, Markus Wagner, Stefan Kaulfuß, Charles L. Cai, Eleni Lagkadinou, Michael Jeffers, Carol E. Peña, Ghazaleh Tabatabai - Clinical Cancer Research 2021 cited by 65

  24. Gemcitabine: metabolism, mechanisms of action, and self-potentiation.

    Authors: William Plunkett, Peng Huang, Yi-Zheng Xu, Volker Heinemann, Ralf Grunewald, Varsha Gandhi - 1995 cited by 756